TORONTO and BENGALURU, India, Oct. 23, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today ...
Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has received an approval from Health Canada for chronic autoimmune conditions treatment medications Yesintek and Yesintek IV. The notice of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek (ustekinumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results